- Home
- BIIB vs UAL Comparison
BIIB vs UAL Comparison
Compare BIIB & UAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- UAL
- Stock Information
- Founded
- BIIB 1978
- UAL 1934
- Country
- BIIB United States
- UAL United States
- Employees
- BIIB N/A
- UAL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- UAL Air Freight/Delivery Services
- Sector
- BIIB Health Care
- UAL Consumer Discretionary
- Exchange
- BIIB Nasdaq
- UAL Nasdaq
- Market Cap
- BIIB 25.1B
- UAL 31.6B
- IPO Year
- BIIB 1991
- UAL N/A
- Fundamental
- Price
- BIIB $149.02
- UAL $101.16
- Analyst Decision
- BIIB Buy
- UAL Strong Buy
- Analyst Count
- BIIB 26
- UAL 16
- Target Price
- BIIB $248.00
- UAL $95.70
- AVG Volume (30 Days)
- BIIB 1.6M
- UAL 4.9M
- Earning Date
- BIIB 02-11-2025
- UAL 01-21-2025
- Dividend Yield
- BIIB N/A
- UAL N/A
- EPS Growth
- BIIB 10.05
- UAL N/A
- EPS
- BIIB 11.06
- UAL 8.30
- Revenue
- BIIB $9,607,500,000.00
- UAL $55,994,000,000.00
- Revenue This Year
- BIIB N/A
- UAL $6.56
- Revenue Next Year
- BIIB N/A
- UAL $7.00
- P/E Ratio
- BIIB $13.47
- UAL $12.19
- Revenue Growth
- BIIB N/A
- UAL 6.67
- 52 Week Low
- BIIB $145.07
- UAL $37.02
- 52 Week High
- BIIB $268.30
- UAL $105.09
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- UAL 64.17
- Support Level
- BIIB $145.07
- UAL $90.17
- Resistance Level
- BIIB $149.92
- UAL $97.48
- Average True Range (ATR)
- BIIB 3.81
- UAL 3.70
- MACD
- BIIB 0.05
- UAL -0.47
- Stochastic Oscillator
- BIIB 22.51
- UAL 73.66
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About UAL United Airlines Holdings Inc.
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.